Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1999-05-19
2000-05-30
Ambrose, Michael G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
544244, 546 23, C07F 96512, C07F 96561
Patent
active
060692499
ABSTRACT:
Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.
REFERENCES:
patent: 3524846 (1970-08-01), Moffatt et al.
patent: 4476248 (1984-10-01), Gordon et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4968788 (1990-11-01), Farquhar
patent: 5142051 (1992-08-01), Holy et al.
patent: 5177064 (1993-01-01), Bodor
patent: 5208221 (1993-05-01), Kim et al.
patent: 5386030 (1995-01-01), Kim et al.
patent: 5506347 (1996-04-01), Erion et al.
patent: 5512596 (1996-04-01), Kim et al.
patent: 5514798 (1996-05-01), Bischofberger et al.
patent: 5618964 (1997-04-01), Cheng et al.
Alexander et al., "Investigation of (Oxodioxolenyl)methly Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines", 39:480-486, J Med Chem, 1996.
Arimilli et al., "Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs", 8(6):557-567, Antiviral Chem & Chemo, 1997.
Arimilli et al., "Orally Bioavailable Acyclic Nucleoside Phosphonate Prodrugs: Adefovir Dipivoxil and Bis(POC)PMPA", vol. 3 (accepted for publication), ADV Antiviral Drug Design, 1998.
Benzaria et al., "New Prodrugs of 9-(2-Phosphonomethoxyethyl) Adenine [PMEA]: Synthesis and Stability Studies", 14(3-5):563-565, NUCLS & NUCLT, 1995.
Cannon, Joseph G. (Reviewer), "The Chemistry of the Carbonyl Group", vol. II, Edited by Saul Patai, Book Review, Sep.-1966.
Davidsen et al, "N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist", 37(26):4423-4429, J Med Chem, Dec.-23-1994.
Engel, R., "Phosphonates as Analogues of Natural Phosphates", 77(3):349-367, Chem Rev, 1977.
Farquhar et al, "Biologically Reversible Phosphate-Protective Groups", 72:324-325, J Pharm Sci, 1983.
Flaherty et al., "Synthesis and Selective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-1,2,3,6-tetrahydropryrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)-and (s)-Nordeprenyl", 39:4759-4761, J Med Chem, 1996.
Folkmann et al., "Acyloxymethyl Carbonochloridates. New Intermediates in Prodrug Synthesis", pp. 1159-1166, Synthesis, Dec.-1990.
Hammer et al., "Ether, Carbonate and Urethane Deoxynucleoside Derivatives as Prodrugs", 50:609-622, Acta Chemica Scandinavia, 1996.
Ikeda et al., "Studies on Prodrugs, III. A Convenient and Practical Preparation of Ampicillin Prodrugs", 32:4316-4322, Chem Phar Bull, 1984.
Iyer et al., "Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium)", 30(51):7141:7144, TET LETT, 1989.
Jones et al., "Minireview: nucleotide prodrugs", 27:1-17, Antiviral Res, 1995.
Krise et al, "Prodrugs of phosphates, phosphonates, and phosphinates", 19:287-310, Advanced Drug Delivery Reviews, May-22-1996.
Landgrebe, John A., "Crystallization and Filtration", 3rd edition, pp. 65-77, Theory and Practice in the Organic Laboratory, 1982.
Lindahl et al., "Synthesis of an Acyloxymethyl Prodrug of the Inositol Phosphate Alpha-Trinositol", 15(5):549-554, J Carbohydrate Chemistry, 1996.
Maillard et al., "Adenosine Receptor Prodrugs: Synthesis and Biological Activity of Derivatives of Potent, A1-Selective Agonists", 83(1):46-53, J Pharm Sci, Jan.-1994.
Myerson, Allan S. (editor), "Solutions and Solution Properties", pp. 1 -165, Handbook of Industrial Crystallization, 1993.
Naesens et al., "Antiretroviral Activity and Pharmacokinetics in Mice of Oral Bis(Pivaloyloxymethyl)-9-(2-Phosphonylmethoxyethyl)Adenine, the Bis(Pivaloyloxymethly) Ester Prodrug of 9-(2Phosphonylmethoxyethl)Adenine", 40(1)22-28, Antimicro AG & CHEMO, Jan.-1996.
Robinson et al, "Discovery of the Hemifumarate and (alpha-L-Alanyloxy)methly Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group", 39:10-18, J Med Chem, 1996.
Safadi et al, "Phosphoryloxymethyl Carbamates and Carbonates--Novel Water-Soluble Prodrugs or Amines and Hindered Alcohols", 10(9):1350-1355, Pharm Res, 1993.
Sakamoto et al, "Studies on Prodrugs II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-dioxolen-4-yl)methyl Esters of Ampicillin", 32(6):2241-2248, Chem Pharm Bull, Aug.-19-1983.
Samara et al., "Pharmacokinetic Analysis of Diethylcarbonate Prodrugs of Ibuprofen and Naproxen", 16:201-210, Biopharmaceutics & Drug Disposition, 1995.
Shaw et al., "Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs", 14(12):1824-1829, Pharm Res, 1997.
Srinivas et al., "Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxmethyl) Prodrugs of Acyclic Nucleoside Phosphonates", 37(10:2247-2250, ANTIMICRO AG & CHEMO, Oct.-1993.
Srivastva et al, "Bioreversible Phosphate Protective Groups: Synthesis and Stability of Model Acyloxymethyl Phosphates", 12:118-129, Bioorg Chem, 1984.
Starrett et al, "Synthesis and in vitro evaluation of a phosphonate prodrug: bis (pivaloyloxymethyl)9-(2-phosphonylmethoxyethyl)adenine", 19:267-273, Antiviral Res, 1992.
Starrett et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrug of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)", 37:1857-1864, J Med Chem, 1994.
Sueoka et al., "Pharmacokinetics of Alkoxycarbonyloxy Ester Prodrugs of PMPA in Dogs", Abstract, American Association of Pharmaceutical Science, Western Regional Meeting, Apr. 24-25, 1997.
Sueoka et al., "Pharmacokinetics of Alkoxycarbonyloxy Ester Prodrugs of PMPA in Dogs", Poster, American Association of Pharmaceutical Science, Western Regional Meeting, Apr. 24-25, 1997.
Tsai et al., "Effect of (R)-9-(2-Phosphonylmethoxypropyl)adenine Monotherapy on Chronic SIV Infection in Macaques", 13(8):707-712, AIDS RES & HUM RETRO, 1997.
Tsai et al., "Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine", 270:1197-1199, Science, Nov.-17-1995.
Weller et al., "Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes a Prodrugs of Amidines", 39:3139-3147, J Med Chem, Dec.-20-1995 .
Arimilli Murty N.
Cundy Kenneth C.
Dougherty Joseph P.
Kim Choung U.
Oliyai Reza
Ambrose Michael G.
Gilead Sciences, Inc.
Hensley Max D.
LandOfFree
Antiviral phosphonomethoxy nucleotide analogs having increased o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral phosphonomethoxy nucleotide analogs having increased o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral phosphonomethoxy nucleotide analogs having increased o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1911281